of I Thank quarter The leadership run company's incredibly the you, improvements year. in team progress the in quarter fourth last marked the quite the fourth the execution team frankly made culmination am since of and Bennett. in occurred May Management the XXXX. of a of and proud transition seven by month
clinical schedule on meeting batches of before required completed stability, the with In months plan have XX focused Epinephrine Phase product, of and a AQST-XXX, of and Sublingual lead separate also Film FDA meeting quarter, with X the end Moreover, FDA. CMC the fourth our Aquestive a of X pipeline Phase team we focused the end and end XXXX. its through to registration the regulatory advanced the
cash to a Our than debt last to million XXX high of had completed payments of early our with surpassed licensees, more commercial continued end reduce any the perform doses to overhang, debt ended our the to also at multiple fourth year. Sympazan license Assertio other we at holders collaborations product to of level. the quarter announced quarter and We shipped
to significantly $XX our streamlined costs, in to ongoing through motion winning non-dilutive cash, significant that over in million we deals successfully reduced litigation the reduce a XXXX, In three business executed Sympazan our on generated ongoing dismiss
difficulty] [Technical
diazepam LIBERVANT, for approval tentative a gained buccal film. and case trust
also We held story. true to have our
results said strong In story. the development This compelling. pharmaceutical to-date sometimes the view, simplest during last well as simple I can company most a under both stories you a quarter As be and August, acute clinical and as second was my two in the call with earnings compelling lives to today, as existing medications is rescue patent summer. remains long true it that have just as revenue
This that Now year clear though, Aquestive we to achieving. on there is remain and time focus is focused are milestones it exciting for several XXXX. on an
of progression The first AQST-XXX. is continuing the rapid
and weeks. are data anticipate We clinical the in clinic having additional currently the coming in
will of in As list in shared data determine study. that our this we use pivotal December, help products will the reference we us to
protocol results comments, send have agency's we we the have its will for FDA we study. we to will comments. need, pivotal our received start the pivotal Once the we a revised Once
for FDA. of the today, to continue submission before us third NDA a the a we to end of study to the As of quarter guide through a If with start mid-XXXX track top this having readout line this keep achieved, will on goal XXXX.
us the participated You be active allergy for we and American of as the conference XXXX. Academy month, Asthma Allergy, more in AAAAI. will Immunology, Last see community known the in continue annual to in commonly
Board, our Advisory posters. and other members leaders. interact but thought also Board As presented to Scientific opportunity This not only our four the with us Scientific allergy advocacy disclosed, conference previously gave Advisory groups
for about better the products continue hear of the universal unmet to significant anaphylaxis. message need We for treatment the
that the an continue by hear community oral patients. by also healthcare product We will likely be received and to well
profile to believe landscape distinct of continue product will AQST-XXX, FDA, the continue the development. products Based understand among as interactions competitive as and non-injectable under we on competitive non-injectable refine a the to positioning progress. our with advantage continues to year, AQST-XXX This we
and deteriorate acute and guideline of acutely management “the Thus, for symptoms usually reactions therapy symptoms begin The clear. of anaphylactic The progress quickly. is within anaphylaxis and very literature may minutes”. states, can
autoinjector advisor just with via is of PK has speed FDA importantly, And “similarity also matters. board and to Our preferred”. well-respected us published the it was made and epinephrine scientific absorption as clear, clear stating,
XX a XX that and uptake and between you is important. concentrations, as view resulting of will have XX As rapid autoinjectors a in on within Based patients caregivers, Tmax also two this completed minutes minutes. our uptake AQST-XXX median shown data We from healthcare range. believe approximately rapid know, typically providers, the median studies, Tmax in pharmacokinetic plasma
At commercial growing our the collaborations and focus same on to we our sheet. strengthening time, will balance continue
Let's start span our with commercial collaborations. collaborations continents. that have six now We significant licensing out seven
launch Brazil Our order collaboration in nausea. track to ondansetron has oral on in growth. America we continue Ondif, the is of film see resulted with launch treatment Hypera for strong South This the and of in
on in the and ALS. ROF the efforts. Our forward we collaboration with to coming ROF of Zambon [ph] supporting Oral the Zambon film launching approval look [ph] months, plans Europe resulted in for has Riluzole treatment in their of
look in our with forward finally, as And Pharmanovia and Europe, to collaboration remains bringing patients providers well, to Libervant if approved. in and on we healthcare track Europe
outstanding approximately several XXXX due We including transfer and resulted capital quarter $XX.X an of have changes the have license also on million already XXXX. on XXXX our reimbursement of payment and first one-time $XX to supply costs raising million. additional carried from generated with under pricing. We’ve cash of into agreement Indivior agreement over and reached non-dilutive matters, agreement our focus in a This in recently
contractual that and company several the the I Indivior to between mind, strengthen upon my important in have the am two relationship that updates is agreed we pleased organizations.
resolve and to to we case from excited settlement A Belbuca reached our with $X.X ongoing case resulted a and million to related have Sciences It I'm International patent this infringement on cash also Aquestive. continue one-time regarding that a settlement where BioDelivery Bunavail. appropriate. is our tied payment litigation say cases to up of to in outstanding move
Europe and to in multiple In rights addition, AQST-XXX, we in we potential are China U.S. collaborations pursuing markets, the for potential for are Libervant, and including pursuing the collaborations
these will of there's to continue success, While opportunities. no pursue guarantee we
from the off healthcare point Libervant scheduled exclusivity subject, the will waiting feedback. will and important XXXX for an The have product the to community advocacy epileptic for that as now on before, a stated rather we suffering interacted drug competitive on is patients given with be access and patients than especially providers, seizure we and the have us final learn to a out-licensing this until expire. FDA. As of with when believe product groups We orphan the from same better product clusters, I've Libervant, and as remains disciplined those process remain we more
We Libervant. XXXX for is another critical year believe
of As actively working U.S. for market. Products proposed a have protocol our of The and before, provided the to study information head-to-head the Review and we on clinical data FDA discussed that, the proposed assured the are Libervant the Development Division we've and FDA review products newly “the us the submitted against study. has with Office our Orphan of additional access blocking currently
making Although, timeframe”. respond for we providing date in a all a cannot we're commit to reasonable a to response, efforts precise
market by will the frustrated to responses, are access. continue of pursue While diligently of all us the of U.S. lack we speed
In talk have quarter first continue we and debt several turnaround the the of of to outstanding XX% company. to financial end to in level XXXX reduce XXXX, by market taken we the by about for and Depending will expect our debt We debt steps by the expect further a reduce to our of more story on financials the our over our conditions, XX%. rates, the Ernie may we debt interest refinance overall terms, moment. business. seek sized becomes as right
In XXXX start. momentum a and carry into we our off to XXXX are from conclusion, fast
us of to continuing expanding last sheet U.S. for million year. market raise on and focus out rapidly to is into parameters, capital pivotal progressing further our arrangements towards total expect our and access This strengthening since year, a non-dilutive Our collaborations work study $XX can FDA's the now pursuant Libervant. to licensing AQST-XXX you balance May over
the to With that, Ernie. turn I will line over
